We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Ornithine Aspartate and Vitamin-E Combination Has Beneficial Effects on Cardiovascular Risk Factors in an Animal Model of Nonalcoholic Fatty Liver Disease in Rats.
- Authors
de Freitas, Laura Bainy Rodrigues; Longo, Larisse; Filippi-Chiela, Eduardo; de Souza, Valessa Emanoele Gabriel; Behrens, Luiza; Pereira, Matheus Henrique Mariano; Leonhard, Luiza Cecília; Zanettini, Giulianna; Pinzon, Carlos Eduardo; Luchese, Eduardo; Lima, Guilherme Jorge Semmelmann Pereira; Cerski, Carlos Thadeu; Uribe-Cruz, Carolina; Álvares-da-Silva, Mário Reis
- Abstract
Cardiovascular (CV) disease is the main cause of death in nonalcoholic fatty liver disease (NAFLD), a clinical condition without any approved pharmacological therapy. Thus, we investigated the effects of ornithine aspartate (LOLA) and/or Vitamin E (VitE) on CV parameters in a steatohepatitis experimental model. Adult Sprague Dawley rats were randomly assigned (10 animals each) and treated from 16 to 28 weeks with gavage as follows: controls (standard diet plus distilled water (DW)), NAFLD (high-fat choline-deficient diet (HFCD) plus DW), NAFLD+LOLA (HFCD plus LOLA (200 mg/kg/day)), NAFLD+VitE (HFCD plus VitE (150 mg twice a week)) or NAFLD+LOLA+VitE in the same doses. Atherogenic ratios were higher in NAFLD when compared with NAFLD+LOLA+VitE and controls (p < 0.05). Serum concentration of IL-1β, IL-6, TNF-α, MCP-1, e-selectin, ICAM-1, and PAI-1 were not different in intervention groups and controls (p > 0.05). NAFLD+LOLA decreased miR-122, miR-33a, and miR-186 (p < 0.05, for all) in relation to NAFLD. NAFLD+LOLA+VitE decreased miR-122, miR-33a and miR-186, and increased miR-126 (p < 0.05, for all) in comparison to NAFLD and NAFLD+VitE. NAFLD+LOLA and NAFLD+LOLA+VitE prevented liver collagen deposition (p = 0.006) in comparison to NAFLD. Normal cardiac fibers (size and shape) were lower in NAFLD in relation to the others; and the inverse was reported for the percentage of regular hypertrophic cardiomyocytes. NAFLD+LOLA+VitE promoted a significant improvement in atherogenic dyslipidemia, liver fibrosis, and paracrine signaling of lipid metabolism and endothelial dysfunction. This association should be further explored in the treatment of NAFLD-associated CV risk factors.
- Subjects
NON-alcoholic fatty liver disease; CARDIOVASCULAR diseases risk factors; ASPARTATE aminotransferase; HEPATIC fibrosis; RAT diseases; ORNITHINE
- Publication
Biomolecules (2218-273X), 2022, Vol 12, Issue 12, p1773
- ISSN
2218-273X
- Publication type
Article
- DOI
10.3390/biom12121773